Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer

Clinical Lung Cancer

Volumn 11, Issue 1, 2010, Pages 36-44

  Kumar, Sachin ^a   Guleria, Randeep ^a   Singh, Vikas ^a   Bharti, Alok C ^b   Mohan, Anant ^a   Das, Bhudev C ^c  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INSTITUTE OF CYTOLOGY AND PREVENTIVE ONCOLOGY   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

Biomarker; Cell death; ELISA; Receiver operating characteristic curve

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER REGRESSION; CELL DEATH; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INOPERABLE CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOSOME; PLASMA; PREDICTION; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SMOKING; TREATMENT RESPONSE;

EID: 77249100479     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.006     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Brambilla C, Fievet F, Jeanmart M, et al. Early detection of lung cancer: role of biomarkers. Eur Respir J Suppl 2003; 39:36s-44s.
3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350:379-392
4. Gridelli C, Rossi A, Maione P. Treatment of non-small cell lung cancer: state of the art and development of new biological agents. Oncogene 2003; 22:6629-6638
5. Pfister DG, Johnson DH, Azzoli CG, et al; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unrescetable non-small cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22:330-353
6. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in nonsmallcell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21:2651-2657
7. de Geus-Oei LF, van der Heijden HF, Corstens FH, et al. Predictive and prognostic value of FDG-PET in non-small cell lung cancer: a systematic review. Cancer 2007; 110:1654-1664
8. Pottgen C, Levegrun S, Theegarten D, et al. Value of 18F-fluoro-2-deoxy- d-glucosepositron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006; 12:97-106.
9. Holdenrieder S, Stieber P, v Pawel J, et al. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res 2004; 10:5981-5987
10. Holdenrieder S, Stieber P, v Pawel J, et al. Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments. Ann N Y Acad Sci 2006; 1075:244-257
11. Vollmer RT, Govindan R, Graziano SL, et al. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. Clin Cancer Res 2003; 9:1728-1733
12. Stieber P, Hasholzner U, Bodenmüller H, et al. CYFRA 21-1: A new marker in lung cancer. Cancer 1993; 72:707-713 (Pubitemid 23215254)
13. Molina R, Filella X, Augé JM, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003; 24:209-218
14. Shibayama T, Ueoka H, Nishii K, et al. Complementary roles of pro-gastrinreleasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer 2001; 32:61-69
15. Schneider J, Philipp M, Salewski L, et al. Pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in therapy control of patients with small-cell lung cancer. Clin Lab 2003; 49:35-42.
16. Niho S, Nishiwaki Y, Goto K, et al. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer: comparative evaluation with neuron-specific enolase and carcinoembryonic antigen. Lung Cancer 2000; 27:159-167
17. Holdenrieder S, von Pawel J, Dankelmann E, et al. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in the therapy monitoring of small-cell lung cancer during first-line chemotherapy. Clin Cancer Res 2008; 14:7813-7821
18. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-1717
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92:205-216 (Pubitemid 30099779)
20. Holdenrieder S, Stieber P, Bodenmüller H, et al. Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med 2001; 39:596-605.
21. Holdenrieder S, Stieber P, Förg T, et al. Apoptosis in serum of patients with solid tumours. Anticancer Res 1999; 19:2721-2724
22. Holdenrieder S, Stieber P, Bodenmüller H, et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 2001; 95:114-120
23. Holdenrieder S, von Pawel J, Schalhorn A, et al. Diagnostic relevance of circulating DNA fragments in oncology. J Lab Med 2005; 29:113-129
24. Pujol JL, Molinier O, Ebert W, et al. CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer 2004; 90:2097-2105 (Pubitemid 38869712)
25. Barlési F, Gimenez C, Torre JP, et al. Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. Respir Med 2004; 98:357-362
26. Holdenrieder S, von Pawel J, Dankelmann E, et al. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent nonsmall cell lung cancer. Lung Cancer 2009; 63:128-135
27. Economidou-Karaoglou A, Brasseur F, Lans M, et al. Variations in serum alkaline DNase activity in rats during growth and treatment of tumors sensitive or resistant to therapy. Int J Cancer 1989; 43:956-959
28. Burlingame RW, Volzer MA, Harris J, et al. The effect of acute phase proteins on clearance of chromatin from the circulation of normal mice. J Immunol 1996; 156:4783-4788
29. Gauthier VJ, Tyler LN, Mannik M. Blood clearance kinetics and liver uptake of mononucleosomes in mice. J Immunol 1996; 156:1151-1156
30. Odaka C, Mizuochi T. Role of macrophage lysosomal enzymes in the degradation of nucleosomes of apoptotic cells. J Immunol 1999; 163:5346-5352
31. Gazdar AF. Personalized medicine and inhibition of EGFR signaling in lung cancer. N Engl J Med 2009; 361:1018-1020
32. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009; 28(suppl 1):S24-31.